Neuroprotection for the warrior: Dietary supplementation with omega-3 fatty acids

Military Medicine

Volumn 176, Issue 10, 2011, Pages 1120-1127

  Lewis, Michael D ^a   Bailes, Julian ^b  

^a Defense and Veterans Brain Injury Center   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID;

BRAIN INJURY; HUMAN; MENTAL DISEASE; NUTRITIONAL REQUIREMENT; REVIEW; SOLDIER; UNITED STATES;

BRAIN INJURIES; FATTY ACIDS, OMEGA-3; HUMANS; MENTAL DISORDERS; MILITARY PERSONNEL; NUTRITIONAL REQUIREMENTS; UNITED STATES;

EID: 80053535896     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED-D-10-00466     Document Type: Article

References (116)

1. Deuster PA, Weinstein AA, Sobel A, Young AJ: Warfighter nutrition: current opportunities and advanced technologies report from a Department of Defense workshop. Mil Med 2009; 174 (7): 671-7.
2. Montain SJ, Carvey CE, Stephens MB: Nutritional fitness. Mil Med 2010; 175 (8S): 65-72.
3. Jonas WB, O'Conner FG, Deuster P, Peck J, Shake C, Frost SS: Why total force fitness? Mil Med 2010; 175 (8S): 6-13.
4. Tartibian B, Maleki BH, Abbasi A: The effects of ingestion of omega-3 fatty acids on perceived pain and external symptoms of delayed onset muscle soreness in untrained men. Clin J Sport Med 2009; 19 (2): 115-9.
5. Mullen M: On total force fitness in was and peace. Mil Med 2010; 175 (8S): 1-2.
6. Salem N Jr., Litman B, Kim HY, Gawrisch K: Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36 (9): 945-59.
7. Youdim K, Martin A, Joseph J. Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 2000; 18: 383-99.
8. Calder P: Marine omega-3 fatty acids and inflammation. J Lipid Nutr 2010; 19 (2): 233-44.
9. Mori TA, Woodman RJ: The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 2006; 9 (2): 95-104.
10. Gosselin N, Theriault M, Leclerc S, Montplaisir J, Lassonde M: Neurophysiological anomalies in symptomatic and asymptomatic concussed athletes. Neurosurgery 2006; 58 (6): 1151-61 discussion 1151-61.
11. McCrea M, Guskiewicz KM, Marshall SW, et al: Acute effects and recovery time following concussion in collegiate football players: the NCAA Concussion Study. JAMA 2003; 290 (19): 2556-63.
12. Kelley DS, Siegel D, Vemuri M, Mackey BE: Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 2007; 86 (2): 324-33.
13. Keller DD, Jurgilas S, Perry B, et al: 106: Docosahexanoic Acid (DHA) lowers triglyceride levels and improves low density lipoprotein particle size in a statin-treated cardiac risk population [abstract]. J Clin Lipidol 2007; 1 (2): 151.
14. Marchioli R, Schweiger C, Tavazzi L, Valagussa F: Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lipids 2001; 36 Suppl: S119-26.
15. von Schacky C: Cardiovascular disease prevention and treatment. Prostaglandins Leukot Essent Fatty Acids 2009; 81 (2-3): 193-8.
16. Singer P, Wirth M: Can n-3 PUFA reduce cardiac arrhythmias? Results of a clinical trial. Prostaglandins Leukot Essent Fatty Acids 2004; 71 (3): 153-9.
17. Harris WS, Kris-Etherton PM, Harris KA: Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr Atheroscler Rep 2008; 10 (6): 503-9.
18. Kremer JM, Jubiz W, Michalek A, et al: Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann Intern Med 1987; 106 (4): 497-503.
19. Nelson GJ, Schmidt PS, Bartolini GL, et al: The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 1997; 32 (11): 1129-36.
20. Agren JJ, Hanninen O, Julkunen A, et al: Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels. Eur J Clin Nutr 1996; 50 (11): 765-71.
21. Becker DJ, Gordon RY, Morris PB, et al: Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc 2008; 83 (7): 758-64.
22. Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G: Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 2000; 148 (2): 387-96.
23. Nelson GJ, Schmidt PC, Bartolini GL, Kelley DS, Kyle D: The effect of dietary docosahexaenoic acid on plasma lipoproteins and tissue fatty acid composition in humans. Lipids 1997; 32 (11): 1137-46.
24. Ferretti A, Nelson GJ, Schmidt PC, Bartolini GL, Kelley DS, Flanagan VP: Dietary docosahexaenoic acid reduces the thromboxane/prostacyclin synthetic ratio in humans. J Nutr Biochem 1998; 9: 88-92.
25. Conquer JA, Holub BJ: Effect of supplementation with different doses of DHA on the levels of circulating DHA as non-esterified fatty acid in subjects of Asian Indian background. J Lipid Res 1998; 39 (2): 286-92
26. Stark KD, Holub BJ: Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. Am J Clin Nutr 2004; 79 (5): 765-73.
27. Theobald HE, Chowienczyk PJ, Whittall R, Humphries SE, Sanders TA: LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. Am J Clin Nutr 2004; 79 (4): 558-63.
28. Theobald HE, Goodall AH, Sattar N, Talbot DC, Chowienczyk PJ, Sanders TA: Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr 2007; 137 (4): 973-8.
29. Sanders TA, Gleason K, Griffin B, Miller GJ: influence of an algal triacylglycerol containing docosahexaenoic acid (22: 6n-3) and docosapentaenoic acid (22: 5n-6) on cardiovascular risk factors in healthy men and women. Br J Nutr 2006; 95 (3): 525-31.
30. Yates A, Norwig J, Moarron JC, et al: Evaluation of lipid profiles and the use of omega-3 essential fatty acid in professional footbal players. Sports Health: A Multidisciplinary Approach 2009; 1 (1): 21-30.
31. Nestel P, Shige H, Pomeroy S, Cehun M, Abbey M, Raederstorff D: The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J Clin Nutr 2002; 76 (2): 326-30.
32. Walser B, Stebbins CL: Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise. Eur J Appl Physiol 2008; 104 (3): 455-61.
33. Monahan KD, Wilson TE, Ray CA: Omega-3 fatty acid supplementation augments sympathetic nerve activity responses to physiological stressors in humans. Hypertension 2004; 44 (5): 732-8.
34. Mozaffarian D, Geelen A, Brouwer IA, Geleijnse JM, Zock PL, Katan MB: Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 2005; 112 (13): 1945-52.
35. Huffman DM, Altena TS, Mawhinney TP, Thomas TR: Effect of n-3 fatty acids on free tryptophan and exercise fatigue. Eur J Appl Physiol 2004; 92 (4-5): 584-91.
36. Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L: Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008; 22 (10): 3595-606.
37. Micallef MA, Garg ML: Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals. Atherosclerosis 2009; 204 (2): 476-82.
38. Behan PO, Behan WM, Horrobin D: Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 1990; 82 (3): 209-16.
39. Dyerberg J, Bang HO: Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979; 2 (8140): 433-5.
40. Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR: Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985; 312 (19): 1210-6.
41. Vanschoonbeek K, Feijge MA, Paquay M, et al: Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. Arterioscler Thromb Vasc Biol 2004; 24 (9): 1734-40.
42. Agren JJ, Vaisanen S, Hanninen O, Muller AD, Hornstra G: Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids 1997; 57 (4-5): 419-21.
43. Cobiac L, Clifton PM, Abbey M, Belling GB, Nestel PJ: Lipid, lipoprotein, and hemostatic effects of fish vs fish-oil n-3 fatty acids in mildly hyperlipidemic males. Am J Clin Nutr 1991; 53 (5): 1210-6.
44. Blonk MC, Bilo HJ, Nauta JJ, Popp-Snijders C, Mulder C, Donker AJ: Dose-response effects of fish-oil supplementation in healthy volunteers. Am J Clin Nutr 1990; 52 (1): 120-7.
45. Harker LA, Kelly AB, Hanson SR, et al: Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates. Circulation 1993; 87 (3): 1017-29.
46. Bays HE: Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007; 99 (6A): 35C-43C.
47. Knapp HR: Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 1997; 65 (5 Suppl): 1687S-98S.
48. Leaf A, Jorgensen MB, Jacobs AK, et al: Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994; 90 (5): 2248-57.
49. Bairati I, Roy L, Meyer F: Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty. Circulation 1992; 85 (3): 950-6.
50. DeCaterina R, Giannessi D, Mazzone A, et al: Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation 1990; 82 (2): 428-38.
51. Rogers S, James KS, Butland BK, Etherington MD, O'Brien JR, Jones JG: Effects of a fish oil supplement on serum lipids, blood pressure, bleeding time, haemostatic and rheological variables. A double blind randomised controlled trial in healthy volunteers. Atherosclerosis 1987; 63 (2-3): 137-43.
52. Kaul N, Kreml R, Austria JA, et al: A comparison of fish oil, flaxseed oil and hempseed oil supplementation on selected parameters of cardiovascular health in healthy volunteers. J Am Coll Nutr 2008; 27 (1): 51-8.
53. Kim H-Y, Akbar M, Kim Y-S: Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid. Prostaglandins Leukot and Essent Fatty Acids 2010; 82: 165-72.
54. Heude B, Ducimetiere P, Berr C: Cognitive decline and fatty acid composition of erythrocyte membranes-The EVA Study. Am J Clin Nutr 2003; 77 (4): 803-8.
55. Lim GP, Calon F, Morihara T, et al: A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005; 25 (12): 3032-40.
56. Wurtman RJ, Cansev M, Ulus IH: Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J Nutr Health Aging 2009; 13 (3): 189-97.
57. Devore EE, Grodstein F, van Rooij FJ, et al: Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr 2009; 90 (1): 170-6.
58. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D: Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007; 85 (4): 1142-7.
59. Wu A, Ying Z, Gomez-Pinilla F: Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 2004; 21 (10): 1457-67.
60. Pauwels EK, Volterrani D, Mariani G, Kairemo K: Fatty acid facts, part IV: docosahexaenoic acid and Alzheimer's disease. A story of mice, men and fish. Drug News Perspect 2009; 22 (4): 205-13.
61. Freund-Levi Y, Basun H, Cederholm T, et al: Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008; 23 (2): 161-9.
62. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al: Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63 (10): 1402-8.
63. Hibbeln JR: Depression, suicide and deficiencies of omega-3 essential fatty acids in modern diets. World Rev Nutr Diet 2009; 99: 17-30.
64. Lewis M, Hibblen J, Johnson J, Lin Y, Hyun D, Loewke J: Suicide deaths of active duty U.S. military and omega-3 fatty acid status: a case control comparison. J of Clin Psychiatry 2011 (in press).
65. Hirayama T: Life Style and Mortality. A Large Scale Census-Based Cohort Study in Japan. New York, Karger, 1990.
66. De Vriese SR, Christophe AB, Maes M: In humans, the seasonal variation in poly-unsaturated fatty acids is related to the seasonal variation in violent suicide and serotonergic markers of violent suicide. Prostaglandins Leukot Essent Fatty Acids 2004; 71 (1): 13-8.
67. Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K, Honkalampi K, Viinamaki H: Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry 2001; 58 (5): 512-3.
68. Huan M, Hamazaki K, Sun Y, et al: Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. Biol Psychiatry 2004; 56 (7): 490-6.
69. Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ: Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am J Psychiatry 2006; 163 (6): 1100-2.
70. Hallahan B, Hibbeln JR, Davis JM, Garland MR: Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry 2007; 190: 118-22.
71. Guskiewicz KM, Marshall SW, Bailes J, et al: Recurrent concussion and risk of depression in retired professional football players. Med Sci Sports Exerc 2007; 39 (6): 903-9.
72. Colangelo LA, He K, Whooley MA, Daviglus ML, Liu K: Higher dietary intake of long-chain omega-3 polyunsaturated fatty acids is inversely associated with depressive symptoms in women. Nutrition 2009; 25 (10): 1011-9.
73. Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H: Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 1996; 38 (1): 35-46.
74. Buydens-Branchey L, Branchey M, Hibbeln JR: Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32 (2): 568-75.
75. Ross BM: Omega-3 polyunsaturated fatty acids and anxiety disorders. Prostaglandins Leukot Essent Fatty Acids 2009; 81 (5-6): 309-12.
76. Buydens-Branchey L, Branchey M: n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol 2006; 26 (6): 661-5.
77. Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K, Burgess JR: Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2006; 75 (4-5): 299-308.
78. Iribarren C, Markovitz JH, Jacobs DR Jr., Schreiner PJ, Daviglus M, Hibbeln JR: Dietary intake of n-3, n-6 fatty acids and fish: relationship with hostility in young adults-the CARDIA study. Eur J Clin Nutr 2004; 58 (1): 24-31.
79. Freeman MP: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006; 67 (12): 1954-67 (Erratum J Clin Psychiatry 2007; 68(2): 338).
80. Hibbeln JR: Fish consumption and major depression. Lancet 1998; 351 (9110): 1213.
81. McNamara RK, Hahn CG, Jandacek R, et al: Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry 2007; 62 (1): 17-24.
82. Lin PY: A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68 (7): 1056-61 (Corrections J Clin Psychiatry 2007; 68[9]: 1448).
83. Appleton KM, Rogers PJ, Ness AR: Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010; 91 (3): 757-70.
84. Hartl R, Gerber LM, Ni Q, Ghajar J: Effect of early nutrition on deaths due to severe traumatic brain injury. J Neurosurg 2008; 109 (1): 50-6.
85. Schaefer EJ, Bongard V, Beiser AS, et al: Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006; 63 (11): 1545-50.
86. Guskiewicz KM, Marshall SW, Bailes J, et al: Association between recurrent concussion and late-life cognitive impairment in retired professional football players. Neurosurgery 2005; 57 (4): 719-26 discussion 719-26.
87. Morris MC, Evans DA, Bienias JL, et al: Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60 (7): 940-6.
88. Giza CC, Hovda DA: The neurometabolic cascade of concussion. J Athl Train 2001; 36 (3): 228-35.
89. Henry LC, Tremblay S, Boulanger Y, Ellemberg D, Lassonde M: Neurometabolic changes in the acute phase after sports concussions correlate with symptom severity. J Neurotrauma 2010; 27 (1): 65-76.
90. Vagnozzi R, Signoretti S, Tavazzi B, et al: Temporal window of metabolic brain vulnerability to concussion: a pilot 1H-magnetic resonance spectroscopic study in concussed athletes-part III. Neurosurgery 2008; 62 (6): 1286-95 discussion 95-6.
91. Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH: Chronic traumatic encephalopathy in a National Football League player. Neurosurgery 2005; 57 (1): 128-34 discussion 128-34.
92. Omalu BI, DeKosky ST, Hamilton RL, et al: Chronic traumatic encephalopathyin a national football league player: part II. Neurosurgery 2006; 59 (5): 1086-92 discussion 92-3.
93. Cantu RC: Chronic traumatic encephalopathy in the National Football League. Neurosurgery 2007; 61 (2): 223-5.
94. Omalu BI, Bailes J, Hammers JL, Fitzsimmons RP: Chronic traumatic encephalopathy, suicides and parasuicides in professional American athletes: the role of the forensic pathologist. Am J Forensic Med Pathol 2010; 31 (2): 130-2.
95. Bailes JE, Mills JD: Docosahexaenoic acid reduces traumatic axonal injury in a rodent head injury model. J Neurotrauma 2010; 27 (9): 1617-24.
96. Mills JD, Hadley K, Bailes JE: Dietary supplementation with the omega-3 fatty acid docosahexaenoic acid: the first neuro-prophylactic for traumatic brain injury? Neurosurgery 2011; 68 (2): 474-81.
97. Babcock AA, Wirenfeldt M, Holm T, et al: Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation. J Neurosci 2006; 26 (49): 12826-37.
98. Calder PC: Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients. Braz J Med Biol Res 2003; 36 (4): 433-46.
99. Lonergan PE, Martin DS, Horrobin DF, Lynch MA: Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide-induced dysfunction in rat hippocampus. J Neurochem 2004; 91 (1): 20-9.
100. Jump DB: Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol 2002; 13 (2): 155-64.
101. Bazan NG: Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 2005; 15 (2): 159-66.
102. Wang HG, Pathan N, Ethell IM, et al: Ca2 + -induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999; 284 (5412): 339-43.
103. Marklund N, Salci K, Lewen A, Hillered L: Glycerol as a marker for post-traumatic membrane phospholipid degradation in rat brain. Neuroreport 1997; 8 (6): 1457-61.
104. Hogyes E, Nyakas C, Kiliaan A, Farkas T, Penke B, Luiten PG: Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience 2003; 119 (4): 999-1012.
105. Wang X, Zhao X, Mao ZY, Wang XM, Liu ZL: Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures. Neuroreport 2003; 14 (18): 2457-61.
106. Pan HC, Kao TK, Ou YC, et al: Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J Nutr Biochem 2009; 20 (9): 715-25.
107. Mills JD, Bailes JE, Sedney CL, Hutchins H, Sears B: Omega-3 fatty acid supplementation and reduction of traumatic axonal injury in a rodent head injury model. J Neurosurg 2011; 114 (1): 77-84. Epub 2010 Jul 16.
108. Wu A, Ying Z, Gomez-Pinilla F: Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J Neurotrauma 2007; 24 (10): 1587-95.
109. Belayev L, Khoutorova L, Atkins KD, Bazan NG: Robust docosahexaenoic acid-mediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke 2009; 40 (9): 3121-6.
110. Cao DH, Xu JF, Xue RH, Zheng WF, Liu ZL: Protective effect of chronic ethyl docosahexaenoate administration on brain injury in ischemic gerbils. Pharmacol Biochem Behav 2004; 79 (4): 651-9.
111. King VR, Huang WL, Dyall SC, Curran OE, Priestley JV, Michael-Titus AT: Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat. J Neurosci 2006; 26 (17): 4672-80.
112. Huang WL, King VR, Curran OE, et al: A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain 2007; 130 (Pt 11): 3004-19.
113. Heller AR, Rossler S, Litz RJ, et al: Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med 2006; 34 (4): 972-9.
114. McClave SA, Martindale RG, Vanek VW, et al: Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr 2009; 33 (3): 277-316.
115. Martindale RG, McClave SA, Vanek VW, et al: Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive summary. Crit Care Med 2009; 37 (5): 1757-61.
116. Roberts L, Bailes J, Dedhia H, et al: Surviving a mine explosion. J Am Coll Surg 2008; 207 (2): 276-83.